Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3849

Sort by

Sort Order Select

Journal Articles

How I incorporate novel agents into the treatment of classical Hodgkin lymphoma

Narendranath Epperla, Alex F. Herrera

Blood (2021) 138 (7): 520–530.

https://doi.org/10.1182/blood.2020007900

Published: 2021

Journal Articles

Mutational landscape of gray zone lymphoma

Blood (2021) 137 (13): 1765–1776.

https://doi.org/10.1182/blood.2020007507

Published: 2021

Includes: Supplemental data

Journal Articles

Protect our children: Hodgkin lymphoma survivors

Nancy L. Bartlett

Blood (2021) 137 (11): 1433–1434.

https://doi.org/10.1182/blood.2020010320

Published: 2021

Journal Articles

Subsequent neoplasms in pediatric Hodgkin lymphoma

Blood (2021) 137 (11): 1562.

https://doi.org/10.1182/blood.2021011303

Published: 2021

Journal Articles

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Lisa Giulino-Roth, Qinglin Pei, Allen Buxton, Rizvan Bush, Yue Wu, Suzanne L. Wolden, Louis S. Constine, Kara M. Kelly, Cindy L. Schwartz, Debra L. Friedman

Blood (2021) 137 (11): 1449–1456.

https://doi.org/10.1182/blood.2020007225

Published: 2021

Includes: Supplemental data

Journal Articles

PD-1 blockade for untreated Hodgkin lymphoma

Alison J. Moskowitz

Blood (2021) 137 (10): 1271–1272.

https://doi.org/10.1182/blood.2020009281

Published: 2021

Journal Articles

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O’Shea, Leo I. Gordon, Jane N. Winter

Blood (2021) 137 (10): 1318–1326.

https://doi.org/10.1182/blood.2020007400

Published: 2021

Includes: Supplemental data

Journal Articles

Hodgkin and Reed-Sternberg–like cells infected with human T-cell leukemia virus type 1

Yuma Tsuruta, Kennosuke Karube

Blood (2020) 136 (2): 257.

https://doi.org/10.1182/blood.2020005936

Published: 2020

Journal Articles

NLP Hodgkin lymphoma: can we get away with less?

Alison J. Moskowitz

Blood (2020) 135 (26): 2329–2330.

https://doi.org/10.1182/blood.2020005876

Published: 2020

Journal Articles

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Blood (2020) 135 (10): 735–742.

https://doi.org/10.1182/blood.2019003127

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Kirsty Wienand, Atanas Kamburov, Gabriel K. Griffin, Pei-Hsuan Chen, Ana Lako, Robert A. Redd, Claire M. Cote, Matthew D. Ducar, Aaron R. Thorner, Scott J. Rodig, Gad Getz, Margaret A. Shipp

Blood (2019) 134 (26): 2369–2382.

https://doi.org/10.1182/blood.2019002067

Published: 2019

Includes: Supplemental data

Journal Articles

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Sanjay S. Patel, Jason L. Weirather, Mikel Lipschitz, Ana Lako, Pei-Hsuan Chen, Gabriel K. Griffin, Philippe Armand, Margaret A. Shipp, Scott J. Rodig

Blood (2019) 134 (23): 2059–2069.

https://doi.org/10.1182/blood.2019002206

Published: 2019

Includes: Supplemental data

Journal Articles

Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)

Catherine Diefenbach, MD, Linda Lam, PhD, Bruce G. Raphael, MD, Kenneth B. Hymes, MD, Michael L. Grossbard, MD, Tibor Moskovits, MD, Peter Martin, FRCPC, MD MS, Jia Ruan, MD PhD, John P. Leonard, MD, Pratip Chattopadhyay, PhD

Blood (2019) 134 (Supplement_1): 3980.

https://doi.org/10.1182/blood-2019-128366

Published: 2019

Journal Articles

Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-Dimer, CRP, Vwf and TNF-α. Interrelationship between Thrombogenesis and Inflammation

Fakiha Siddiqui, Emily Bontekoe, Darko Antic, PhD, Debra Hoppensteadt, PhD, Grigoris Gerotziafas, MD PhD, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 5239.

https://doi.org/10.1182/blood-2019-128440

Published: 2019

Journal Articles

Toxicities of Brentuximab Vedotin in Children and Adolescents with Hodgkin Lymphoma

Ruetima Titapiwatanakun, MD, Sukhjeet Singh Batth, MD, Katherine Baker, NP, Wendy Tcheng, MD, Karen S. Fernandez, MD

Blood (2019) 134 (Supplement_1): 5298.

https://doi.org/10.1182/blood-2019-122973

Published: 2019

Journal Articles

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Edus H. Warren, MD PhD, David M. Kurtz, MD PhD, Hilary Coye, PA-C, Jacquelin Vandermeer, BS, Hongyan Du, MD, Adam Greenbaum, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5299.

https://doi.org/10.1182/blood-2019-124997

Published: 2019

Journal Articles

Characteristics and Outcomes of Patients with Lymphoma Who Developed Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome - a Retrospective Analysis of the Polish Adult Leukemia Group

Aleksandra Golos, MD PhD, Krzysztof Mądry, MD PhD, Karol Lis, Marta Sobas, MD, Agnieszka Ożańska, Magdalena Czemerska, Dorota Hawrylecka, Agnieszka Stelmach-Gołdyś, Karolina Chromik, Bartosz Pula, Ewa Lech-Maranda, MD PhD, Joanna Gora Tybor, MD PhD

Blood (2019) 134 (Supplement_1): 5422.

https://doi.org/10.1182/blood-2019-125711

Published: 2019

Journal Articles

Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients

Sunnia T Chen, BS, Nicholas J Boddicker, PhD, Matthew J. Maurer, MS, Cristine Allmer, BS, Dennis P. Robinson, Grzegorz Nowakowski, MD, Thomas M. Habermann, MD, Susan L Slager, PhD, Carrie A. Thompson, MD, James R. Cerhan, MD PhD

Blood (2019) 134 (Supplement_1): 5215.

https://doi.org/10.1182/blood-2019-128775

Published: 2019

Journal Articles

Liquid Biopsy Is Useful to Identify the Genetic Profile of NHL-B at Diagnosis in Different Histological Subtypes

Mariana Bastos-Oreiro, MD PhD, Julia Suárez González, Natalia Carolina Carrión, Cristina Andres, Solsireey Moreno, Diego Carbonell, Mr, María Chicano Lavilla, PhD, Gillen Oarbeascoa, MD, Francisco Diaz Crespo, Javier Menarguez, MD PhD, José Luis Díez-Martín, MD PhD, Ismael Buño, PhD, Carolina Martínez-Laperche

Blood (2019) 134 (Supplement_1): 5216.

https://doi.org/10.1182/blood-2019-129868

Published: 2019

Journal Articles

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Stephen B Howell, MD, Hongying Zhang, MD PhD, William G Rice, PhD

Blood (2019) 134 (Supplement_1): 5477.

https://doi.org/10.1182/blood-2019-130784

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

How I incorporate novel agents into the treatment of classical Hodgkin lymphoma

Mutational landscape of gray zone lymphoma

Protect our children: Hodgkin lymphoma survivors

Subsequent neoplasms in pediatric Hodgkin lymphoma

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

PD-1 blockade for untreated Hodgkin lymphoma

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Hodgkin and Reed-Sternberg–like cells infected with human T-cell leukemia virus type 1

NLP Hodgkin lymphoma: can we get away with less?

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)

Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-Dimer, CRP, Vwf and TNF-α. Interrelationship between Thrombogenesis and Inflammation

Toxicities of Brentuximab Vedotin in Children and Adolescents with Hodgkin Lymphoma

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Characteristics and Outcomes of Patients with Lymphoma Who Developed Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome - a Retrospective Analysis of the Polish Adult Leukemia Group

Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients

Liquid Biopsy Is Useful to Identify the Genetic Profile of NHL-B at Diagnosis in Different Histological Subtypes

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only